Understanding how a specific protein protects against Alzheimer's disease
Mechanisms of Peroxiredoxin 6 Endowed Protection in Alzheimer’s Disease
This study is looking at how a protein called PRDX6 helps brain cells called astrocytes protect against damage from beta-amyloid, which is linked to Alzheimer's disease, and it aims to find ways to keep our brains healthier as we age.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10773024 on NIH RePORTER |
What this research studies
This research investigates the role of the protein Peroxiredoxin 6 (PRDX6) in protecting brain cells from damage caused by beta-amyloid (Aβ) deposits, which are linked to Alzheimer's disease. The study focuses on how astrocytes, a type of brain cell, respond to Aβ and how PRDX6 may enhance their protective functions. By exploring the molecular mechanisms involved, the research aims to uncover new insights into how these cells can help maintain brain health and potentially slow the progression of Alzheimer's. The approach includes using mouse models to observe the effects of PRDX6 on astrocyte behavior in the context of Aβ accumulation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for or diagnosed with Alzheimer's disease, particularly those with genetic variants affecting microglial function.
Not a fit: Patients with advanced Alzheimer's disease or those without any genetic predisposition to the condition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the brain's natural defenses against Alzheimer's disease.
How similar studies have performed: Previous research has shown that targeting glial cell functions can be beneficial in Alzheimer's models, suggesting that this approach may yield promising results.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Sadowski, Martin Joseph — New York University School of Medicine
- Study coordinator: Sadowski, Martin Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.